Termination of Early Pregnancy in Scarred Uterus With Lletrozole and Misoprostol Compared to Misoprostol Alone

NCT ID: NCT05067309

Last Updated: 2021-10-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-01

Study Completion Date

2022-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Termination of early pregnancy in scarred uterus with letrozole and misoprostol compared to Misoprostol alone

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Termination of Early Pregnancy in Scarred Uterus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Missed abortion received letrozole then misoprostol

Letrozole 2.5mg

Intervention Type DRUG

Missed abortion received letrozole then misoprostol

Missed abortion received misoprostol alone

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Letrozole 2.5mg

Missed abortion received letrozole then misoprostol

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Minimum age of 18 years for mother.

* Non-viable fetus (missed abortion or blighted ovum) in the 1st trimester of pregnancy evidenced by criteria for diagnosis by TVS .
* Previous C.S or Myomectomy (1 or more )
* lack of any maternal diseases such as: heart disease, asthma, history of thromboembolism, cancer, renal failure, and liver diseases.

Exclusion Criteria

* \* Medical problem in patient

* Emergency conditions which need intervention .
* History of allergy to misoprostol or letrozole drugs.
Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ahmed Elsayed Aref

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed Elsayed Aref

Ahmed Elsayed Aref

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ahmed Elsayed Aref

Sohag, , Egypt

Site Status

Ahmed Elsayed Aref

Sohag, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ahmed Elsayed Aref

Role: primary

01097993202

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Soh-Med-21-09-07

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Termination Of Anembryonic Pregnancy
NCT02573051 WITHDRAWN PHASE2
Misoprostol in Missed Abortion
NCT06818903 NOT_YET_RECRUITING